Anti-CD16-anti-CD30 monoclonal antibody

Drug Profile

Anti-CD16-anti-CD30 monoclonal antibody

Alternative Names: Anti-CD16-anti-CD30 bispecific monoclonal antibody; Anti-CD30-anti-CD16 bispecific monoclonal antibody; Anti-CD30-anti-CD16 monoclonal antibody

Latest Information Update: 22 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 22 Mar 2007 Discontinued - Phase-II for Hodgkin's disease in Germany (IV-infusion)
  • 14 Sep 2000 A phase II study has been added to the Cancer therapeutic trials and pharmacodynamics sections
  • 28 May 1997 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top